Work

132P Efficacy and safety of tislelizumab plus surufatinib in later-line treatment of metastatic colorectal cancer: A single-arm, phase ii trial with a negative result

Year: 2025

Type: article

Abstract: Patients with metastatic colorectal cancer (mCRC) progressing on standard chemotherapies often maintain good performance status, but effective treatment options are limited, especially for microsatellite-stable (MSS) tumors. Preclinical evidence supports synergy between PD-1 blockade and anti-angiogenic therapy. This phase II trial evaluated the combination of tislelizumab (anti-PD-1 antibody) and surufatinib (inhibitor of VEGFR1–3, FGFR1, CSF-1R) in refractory mCRC.

Source: Immuno-Oncology Technology

DOI: 10.1016/j.iotech.2025.101216

Author: H. Xu

Institutions: University of Science and Technology of China, Anhui Provincial Hospital

Language: English

Topic: Colorectal Cancer Treatments and Studies

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $3,340